Compare PBYI & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBYI | HBIO |
|---|---|---|
| Founded | 2010 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 33.8M |
| IPO Year | N/A | 2000 |
| Metric | PBYI | HBIO |
|---|---|---|
| Price | $5.54 | $0.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $7.00 | $2.50 |
| AVG Volume (30 Days) | 395.4K | ★ 868.9K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $211,995,000.00 | $87,371,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.22 |
| P/E Ratio | $7.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $0.28 |
| 52 Week High | $6.12 | $2.28 |
| Indicator | PBYI | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 62.65 |
| Support Level | $4.84 | $0.68 |
| Resistance Level | $5.92 | $0.78 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 68.47 | 69.46 |
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.